From reactive to curative

Pioneer the next era of curative-intent studies with the #1 trusted partner to operationalize MRD-guided trials at scale¹

See the Evidence Request Consultation

Molecular residual disease (MRD) testing detects cancer recurrence at the earliest stages, opening a window to intervene before radiographic progression.

Serial ctDNA testing diagram: ctDNA negative results, ctDNA positive result with negative scans, randomization to novel treatment or control arm, and ctDNA clearance as early efficacy readout

Improved Patient Outcomes

Signatera-positive patients benefitted from therapy

55%

median Overall Survival (OS) improvement

2x

median DFS improvement

Signatera-negative patients were spared adjuvant therapy

100%

OS at 1 year without adjuvant therapy

Regulatory Approval

1st

FDA-approved MRD
Companion Diagnostic (CDx)³

Read IMvigor011 press release

Trusted by leading biopharma across pivotal studies

ALPHA3

Pivotal Phase 2 trial evaluating an investigational allogeneic CAR T product as part of 1L consolidation treatment in LBCL

Read press release

STELLAR-316

Phase 3 trial of zanzalintinib in MRD-positive CRC patients enrolling on Signatera positivity after curative-intent treatment

Read press release

AVTA 30-01

Global Phase 3 trial evaluating a first-in-class oral immunotherapy in patients with locally advanced head and neck squamous cell carcinoma

Read press release

40+ studies

ongoing and planned

See our studies

Study Planning

Study Execution

Commercialization

Study Planning

RWD for Study Feasibility & Design

Define target patient populations, refine eligibility criteria, and assess enrollment feasibility

Study Execution

Ultrasensitive MRD & Diagnostics

Detect molecular recurrence earlier (below 1 PPM) and characterize mechanisms of response and resistance⁴

See assay capabilities

Patient Identification & Matching

Identify MRD-positive patients in real-time from commercial testing to accelerate study recruitment

Explore patient matching

Commercialization

CDx Commercialization

Backed by the #1 trusted MRD partner, with global regulatory experience and the broadest commercial footprint¹

Read CDx approval

RWD for Study Feasibility & Design

Define target patient populations, refine eligibility criteria, and assess enrollment feasibility

Ultrasensitive MRD & Diagnostics

Detect molecular recurrence earlier (below 1 PPM) and characterize mechanisms of response and resistance⁴

See assay capabilities

Patient Identification & Matching

Identify MRD-positive patients in real-time from commercial testing to accelerate study recruitment

Explore patient matching

CDx Commercialization

Backed by the #1 trusted MRD partner, with global regulatory experience and the broadest commercial footprint¹

Read CDx approval

Broad commercial scale built to accelerate trial recruitment

> 1,000

clinics per quarter ordering Signatera⁵

> 50%

of oncologists have ordered Signatera⁵

> 400k

patients tested with Signatera⁵

MRD Testing in Routine Care

Patient demographic distribution across the United States

Patient identification for interventional trials

TOMR Network
Patient Matching

Trial A

Trial B

Trial C

Request a study design consultation

Get tailored guidance on trial design and patient identification strategy, based on your program's specific needs

* Indicates a required field

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

1. Based on RBC Capital Markets analyst estimates (June 2026) and Natera internal data (August 2026)

2. Powles T, Kann AG, Castellano D, et al. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. New England Journal of Medicine. Published online October 20, 2025. doi:10.1056/NEJMoa2508652. *Treated with atezolizumab vs. placebo - % improvement based on median OS and DFS in the IMvigor 011 study, a global trial in partnership with Genentech, a member of the Roche Group.

3. Signatera CDx is an FDA approved Companion Diagnostic test intended to identify Muscle Invasive Bladder Cancer (MIBC) patients with ctDNA MRD positive status who may benefit from atezolizumab. For the approved intended use, product limitations and detailed performance characteristics, refer to FDA approved labeling under the PMA P230006.

4. Cabel et al. ESMO 2024, using CLARITY Fixed Research Use Only (RUO) assay

5. Source: Natera internal data as of January 2026

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test.
The tests have not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.
© 2026 Natera, Inc. All Rights Reserved.

Privacy Policy California Notice of Collection HIPAA Notice IT Security Compliance Terms Licenses

From reactive to curative

Treatment on MRD (TOMR)

Demonstrated registrational study success and approval

Trusted by leading biopharma across pivotal studies

ALPHA3

STELLAR-316

AVTA 30-01

Capabilities spanning the development lifecycle

RWD for Study Feasibility & Design

Ultrasensitive MRD & Diagnostics

Patient Identification & Matching

CDx Commercialization

RWD for Study Feasibility & Design

Ultrasensitive MRD & Diagnostics

Patient Identification & Matching

CDx Commercialization

Broad commercial scale built to accelerate trial recruitment

Request a study design consultation

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.